A subscription to JoVE is required to view this content. Sign in or start your free trial.

Method Article

Human Microglia-like Cells: Differentiation from Induced Pluripotent Stem Cells and In Vitro Live-cell Phagocytosis Assay using Human Synaptosomes

5K views

⸱

DOI:

10.3791/64323

⸱

August 18th, 2022

 , 
1Department of Neurology, University of Massachusetts Chan Medical School, 2Translation Science Program, Morningside Graduate School of Biomedical Sciences, University of Massachusetts Chan Medical School

In This Article

Summary

This protocol describes the differentiation process of human induced pluripotent stem cells (iPSCs) into microglia-like cells for in vitro experimentation. We also include a detailed procedure for generating human synaptosomes from iPSC-derived lower motor neurons that can be used as a substrate for in vitro phagocytosis assays using live-cell imaging systems.

Abstract

Microglia are the resident immune cells of myeloid origin that maintain homeostasis in the brain microenvironment and have become a key player in multiple neurological diseases. Studying human microglia in health and disease represents a challenge due to the extremely limited supply of human cells. Induced pluripotent stem cells (iPSCs) derived from human individuals can be used to circumvent this barrier. Here, it is demonstrated how to differentiate human iPSCs into microglia-like cells (iMGs) for in vitro experimentation. These iMGs exhibit the expected and physiological properties of microglia, including microglia-like morphology, expression of proper markers, and active phagocytosis. Additionally, documentation for isolating and labeling synaptosome substrates derived from human iPSC-derived lower motor neurons (i3LMNs) is provided. A live-cell, longitudinal imaging assay is used to monitor engulfment of human synaptosomes labeled with a pH-sensitive dye, allowing for investigations of iMG's phagocytic capacity. The protocols described herein are broadly applicable to different fields that are investigating human microglia biology and the contribution of microglia to disease.

Introduction

Microglia are the resident immune cells in the central nervous system (CNS) and play a crucial role in developing the CNS. Microglia are also important in the adult brain for maintaining homeostasis and actively responding to trauma and disease processes. Cumulative evidence shows that microglia are key contributors to the pathogenesis of multiple neurodevelopmental and neurodegenerative diseases1,2. Although current knowledge about microglial biology has been predominately derived from mouse models, recent studies have elucidated important differences between murine and human microglia, underscoring the need for developing technologies to study the genetics and biological functions of human microglia3,4. Isolation of microglia from dissected primary tissue can severely modify microglia properties5, potentially confounding results acquired with such cells. The overall goal of this method is to differentiate human iPSCs into iMGs, thereby providing a cell culture system to study human microglia under basal conditions. Furthermore, a phagocytosis assay using a fully human model system is included herein as a means to study the functionality of iMGs, both as a quality control measure and to assess iMG dysfunction in the context of disease.

Multiple protocols for microglia differentiation from iPSCs have recently emerged in the literature6,7,8,9,10. Potential disadvantages of some protocols include extended or long periods of differentiation, the addition of multiple growth factors, and/or complex experimental procedures6,9,10. Here, a "user-friendly" differentiation method is demonstrated that recapitulates aspects of microglia ontogeny through differentiation of iPSCs into precursor cells termed primitive macrophage precursors (PMPs)7,11. PMPs are generated as described previously, with some optimizations presented herein12. The PMPs mimic MYB-independent yolk-sac-derived macrophages, which give rise to microglia during embryonic development by invading the brain before blood-brain barrier closure13. To terminally differentiate PMPs into iMGs, we used a fast and simplified monoculture method based on protocols by Haenseler et al. and Brownjohn et al., with some modifications to generate an efficient microglia differentiation method in which iMGs robustly express microglia-enriched markers7,8. This differentiation method can be reproduced in laboratories with expertise in the culture of iPSCs and with research goals aiming to study microglia biology using a human model system.

iPSC-derived microglia represent a biologically relevant source of human microglia for in vitro experimentation and are an important tool to investigate microglial canonical functions, including phagocytosis. Microglia are the professional phagocytes of the brain and CNS, where they clear cell debris, aggregated proteins, and degraded myelin14. Microglia also function in synaptic remodeling by engulfing synapses and in the defense against external infections through phagocytosis of pathogens15,16. In this protocol, phagocytosis by iMGs is assessed using human synaptosomes as material for iMG engulfment. To this end, a description for isolating synaptosomes derived from human i3LMNs is described. The i3LMN-derived human synaptosomes are labeled with a pH-sensitive dye that allows for quantification of synaptosomes localized within acidic compartments during phagosome processing and degradation in vitro. A phagocytosis assay using live-cell microscopy is shown for monitoring the dynamic process of microglia engulfment in real-time. This functional assay establishes a basis to investigate possible defects in microglial phagocytosis in health and disease using a complete human system.

Access restricted. Please log in or start a trial to view this content.

Protocol

NOTE: All the reagents used in this protocol must be sterile, and all the steps must be performed in a biosafety cabinet under sterile conditions. All the iPSC lines, as well as maintenance and differentiation media, are described in the Table of Materials. The microglia differentiation method illustrated below is based on previously published protocols7,8,12 with new modifications described herein.

1. Microglia differentiation

NOTE: An overview of the protocol is summarized in Figure 1.

  1. Induced pluripotent stem cell (iPSC) culture
    NOTE: Further details describing iPSC culture techniques can be found elsewhere17.
    1. Thawing and maintenance
      1. Prepare iPSC medium, aliquot the medium, and store at -20 °C for up to 6 months. Thaw the aliquots overnight at 4 °C and use them for up to 1 week. Leave the media at ambient temperature for at least 1 h before use.
      2. Coat the wells of a 6-well plate by adding 1 mL of 10 µg/mL of laminin 521 diluted in DPBS containing calcium and magnesium18. Keep the plates in an incubator at 37 °C and 5% CO2 for at least 2 h or preferably overnight. Once diluted, store the laminin at 4 °C for 3 months.
      3. Prepare 10 mM Rho kinase inhibitor Y27632 (ROCK Inhibitor) stock solution by diluting in sterile water. Make single-use aliquots of ROCK inhibitor solution and store them at -20 °C for up to 1 year.
      4. Prepare 0.5 mM EDTA by diluting the stock solution of 0.5 M EDTA in DPBS.
      5. To thaw a vial of frozen iPSCs, place the vial in a water bath at 37 °C until it is mostly thawed. Immediately transfer the content of the vial to a 15 mL conical tube containing 4 mL of iPSC medium. Centrifuge at 500 × g for 1 min.
      6. Aspirate the supernatant and resuspend the cells by adding 1 mL of iPSC medium containing 10 µM ROCK inhibitor slowly against the wall of the tube to avoid disturbance of the colonies.
      7. Add 1.5 mL of iPSC medium containing 10 µM ROCK inhibitor to each of the coated wells and transfer the resuspended colonies drop by drop to the wells containing the medium.
        NOTE: Use 5-7 drops from step 1.1.1.6 for culture maintenance but adjust the optimal seeding density for every iPSC line.
      8. Evenly distribute the cells in the wells by manually shuffling the plate side-to-side and back to front. Place the cells in an incubator at 37 °C and 5% CO2. The next day, completely replace the medium by adding fresh iPSC medium without ROCK inhibitor.
      9. For maintenance, change the medium every day until the cells reach 80% confluency.
        NOTE: The cells can be maintained without changing the medium for 2 days if the iPSC medium used allows a flexible feeding schedule. It is advised to limit this to one time per passage and only if the cells are less than 50% confluent.
    2. Splitting
      1. Aspirate the medium and wash the cells with 1 mL of DPBS (without calcium and magnesium).
      2. To dislodge the cells, add 1 mL of 0.5 mM EDTA and incubate for 2-3 min at room temperature until the edges of the cell colonies lift from the surface of the well. Wash the cells again with DPBS and add 1 mL of iPSC medium.
      3. Dissociate the cell colonies by gently scraping them using a cell lifter. Scrape each area of the well only once to avoid disturbing the colonies.
        NOTE: Alternative methods to dislodge the colonies from the well can be found elsewhere17.
      4. Using a 1 mL pipette tip, collect the cells and transfer them drop by drop at a 1:6 ratio (cells to medium) into precoated wells (as mentioned in step 1.1.1.2) containing 1.5 mL of iPSC medium.
  2. iPSC differentiation to microglia-like cells (iMGs)
    NOTE: The small molecules and growth factors are dissolved in sterile-filtered 0.1% bovine serum albumin in DPBS to a stock concentration 1,000x higher than the final concentration. It is recommended to differentiate iPSCs into iMGs during early passages. Routine karyotyping of iPSC lines is advised.
    1. Prepare standard coating solution
      1. Thaw the stock solution of an extracellular matrix coating reagent on ice at 4 °C overnight.
      2. Prechill microcentrifuge tubes and filter pipette tips at 4 °C.
      3. Aliquot 250 µL of the concentrated extracellular matrix coating reagent into each tube and immediately place on ice. Store the aliquots at -20 °C.
      4. To prepare the coating solution, thaw one of the extracellular matrix coating reagent aliquots on ice at 4 °C overnight.
      5. Add 50 mL of ice-cold DMEM-F12 optimized for growth of human embryonic and induced pluripotent stem cells (referred as to DMEM-F12) media to a prechilled conical tube and keep it on ice.
      6. Chill a 1 mL pipette tip by pipetting ice-cold DMEM-F12 up and down multiple times, and then immediately use the pipette tip to transfer 250 µL of the extracellular matrix coating reagent into the conical tube containing the DMEM-F12 medium.
        NOTE: The standard coating solution can be stored for 2 weeks at 4 °C.
    2. Embryoid body (EB) formation
      1. Prepare EB medium that can be maintained at 4 °C for up to 4 days.
      2. Once iPSCs have reached 80% confluency, dissociate the colonies by washing with 1 mL of DPBS and adding 1 mL of a dissociation reagent for 2 min at 37 °C. Dislodge the colonies using a cell lifter by scraping multiple times to create a single-cell suspension. Collect the cells and transfer everything to a 15 mL conical tube containing 9 mL of DPBS.
      3. Centrifuge the cells at 500 × g for 1 min, remove the supernatant, and resuspend the cells in 1 mL of EB medium. Take 10 µL of cells and dilute 1:1 with Trypan blue. Count the cells with a hemacytometer, and based on the cell count, dilute the cell-stock to a final dilution of 10,000 cells per 100 µL. For plating cells, add 100 µL of the diluted cells per well into a low adherence, round-bottom, 96-well plate.
        NOTE: Generally, 48 wells of the 96-well plate can be obtained from each 80% confluent well of iPSCs.
      4. Centrifuge the plate at 125 × g for 3 min and incubate at 37 °C and 5% CO2 for 4 days. Perform a half-medium change on day 2 by using a multichannel pipette and gently collecting 50 µL of old medium, and then adding back 50 µL of fresh EB medium.
        NOTE: On day 4, iPSCs will form spherical cellular structures termed EBs as described in the results section. The EB differentiation process can be extended up to 7 days, if necessary.
    3. Generation of primitive macrophage precursors (PMPs)
      1. Prepare PMP base medium, sterile-filter, and store it at 4 °C for up to 1 month.
      2. Coat the wells of a 6-well plate by adding 1 mL of ice-cold Matrigel coating solution and incubate at 37 °C and 5% CO2 for at least 2 h or preferably overnight.
      3. On day 4 of EB differentiation, transfer the EBs to the Matrigel-coated wells by collecting the EBs with 1 mL pipette tips (using a pipette). Pipette up and down once or twice to dislodge the EBs from the well. Hold the 6-well plate at a tilted angle to allow for the EBs to settle down at the edge of the well.
        NOTE: Nine or ten EBs can be plated per coated well.
      4. Once all the EBs have settled down, gently pipette and remove the old medium using a 1 mL pipette tip while keeping the EBs at the edge of the well. Add 3 mL of freshly prepared PMP complete medium to each well. Evenly distribute the cells in the wells by manually shuffling the plate side-to-side and back to front. Place the plate in the incubator at 37 °C and 5% CO2.
      5. Do not disturb the plate for 7 days to allow the EBs to attach to the bottom of the well. After that time, perform a half-medium change using PMP complete medium.
        NOTE: At this point, most of the EBs should be attached to the plate. Any floating EBs can be removed.
      6. After 5-7 days, inspect the EBs under a light field microscope at 4x magnification to ensure that they are attached to the bottom of the wells. Change the medium as described in 1.2.3.5. On day 21, perform a complete medium change with 3 mL of PMP complete medium.
        NOTE: Myeloid progenitors floating in the medium may be evident at this point. These cells should be discarded during the medium change.
      7. On day 28, look for round cells referred to as PMPs in the supernatant and collect the medium containing the PMPs using a 10 mL pipette and automatic pipettor. Take care not to disturb the EBs. Transfer the PMPs and the medium to a 15 mL conical tube and proceed as described in step 1.2.4.
        NOTE: Usually PMPs from the same iPSC line can be collected from five wells of a 6-well plate and pooled together in a single 15 mL conical tube.
      8. Add 3 mL of fresh PMP complete medium for further maintenance of the EBs. As PMPs continuously emerge from EBs for more than 3 months, collect them every 4-7 days (do not allow the medium to change color to a yellow tone) as described in steps 1.2.3.7 and 1.2.3.8.
        NOTE: Although PMPs can be collected for several months, they may change their phenotype over time.
    4. Differentiation to iMGs
      1. Prepare iMG base medium (Table of Materials), sterile-filter and store it at 4 °C for up to 3 weeks.
      2. Once the PMPs have been collected into a 15 mL conical tube, centrifuge them at 200 × g for 4 min. Aspirate the supernatant and resuspend the PMPs using 1-2 mL of iMG basal medium. Count the cells using a hemocytometer by taking a small aliquot and diluting 1:1 with Trypan blue.
        NOTE: 0.5-1.5 × 106 PMPs are normally obtained every week depending on the iPSC line and the age of the EB culture.
      3. Centrifuge the rest of the cells again at 200 × g for 4 min. Dilute the PMPs to the desired concentration such that cells are plated at a density of ~105/cm2 on cell culture-treated plates using freshly prepared iMG complete medium. Perform a half-medium change using freshly prepared iMG complete medium every 3-4 days throughout 10-12 days to allow for terminal differentiation.
        NOTE: At this point, the cells should acquire microglia-like morphology. To confirm the commitment of PMPs to microglia fate, immunofluorescence analysis is performed to corroborate the expression of microglia-enriched markers such as purinergic receptor P2RY12 and transmembrane protein 119 (TMEM119)9.
      4. To preserve cell health and viability, perform all the experiments between days 10 to 12 of iMG differentiation.

2. Phagocytosis assay using motor-neuron-derived human synaptosomes

  1. Transcription factor-mediated differentiation of iPSC-derived lower motor neurons (i3LMNs)
    NOTE: A WTC11 line with stable insertion of the hNIL inducible transcription factor cassette containing the neurogenin-2 (NGN2), islet-1 (ISL1), and LIM homeobox 3 (LHX3) transcription factors into the CLYBL safe harbor locus was used for the differentiation process as described previously17. The iPSC line was maintained as described in step 1.1.1 but with the coating conditions described in step 1.2.1. Any extracellular matrix coating reagent can be used for culturing iPSCs that will be used for neuronal differentiation since laminin 521 is not required. All the media are equilibrated to ambient temperature for at least 1 h before use.
    1. Coat 10 cm dishes with 5 mL of standard coating solution as described in step 1.2.1.
      NOTE: Here, 3-4 10 cm dishes were used per differentiation.
    2. Prepare Induction Base medium, sterile-filter, and store it at 4 °C for up to 3 weeks.
    3. Prepare Neuron medium, sterile-filter, and store it at 4 °C for up to 2 weeks.
    4. Prepare borate buffer by mixing 100 mM boric acid, 25 mM sodium tetraborate, and 75 mM sodium chloride in sterile water. Adjust the pH to 8.5 and sterile-filter it.
    5. Once iPSCs have reached 80% confluency, wash the cells with DPBS and dislodge the colonies by adding 0.5 mM EDTA.
      NOTE: Two wells are usually sufficient for each 10 cm dish.
    6. Incubate the cells for 4-5 min at ambient temperature. Remove the EDTA and add 3 mL of DMEM/F12 with HEPES to each well.
    7. Scrape the cells using a cell lifter and use a 10 mL pipette to remove the cells from the bottom of the well by gently pipetting up and down 2-3x.
    8. Collect the cells in a 15 mL conical tube and centrifuge at 300 × g for 3 min.
    9. Resuspend the cells in 3 mL of iPSC medium containing 10 µM ROCK inhibitor and count them using a hemacytometer.
    10. Plate 1.5 × 106 iPSCs in a precoated 10 cm dish with 12 mL of iPSC medium containing 10 µM ROCK inhibitor.
    11. The next day, remove the medium and wash the cells with DPBS. Add 12 mL of freshly prepared Complete Induction medium to induce the expression of the transcription factors.
    12. On day 2, coat 10 cm dishes with 5 mL of neuron coating solution prepared with equal volumes of 0.1 mg/mL of poly-D-lysine and 1 mg/mL of poly-L-ornithine diluted in borate buffer. Incubate overnight at 37 °C and 5% CO2.
    13. On day 3, wash the coated dishes with sterile water 3x, aspirate the water completely, and let the dishes dry by tilting the plates and leaving them partially uncovered inside a biosafety cabinet for at least 1 h at ambient temperature.
    14. Once the dishes have fully dried, coat them with 6 mL of Complete Induction medium supplemented with 15 µg/mL of laminin and 40 µM BrdU for at least 1 h at 37 °C and 5% CO2.
      NOTE: BrdU treatment is recommended to eliminate mitotically active cells and thus to enhance the purity of the neuronal cultures. The effects of BrdU on neuronal health are minimal.
    15. Treat the differentiating cells with 3 mL of dissociation reagent per 10 cm dish and incubate for 3-4 min at ambient temperature.
    16. Add 6 mL of DPBS into the plate without removing the dissociation reagent and pipette the cells in solution up and down 4-5x with a 10 mL pipette to dissociate the cells.
    17. Collect the cell suspension and pass it through a 40 µm cell strainer into a 50 mL conical tube. Add 1 mL of Induction base medium to rinse the strainer.
    18. Centrifuge the cells at 300 × g for 5 min. Aspirate the medium and resuspend the cells in 3 mL of Complete Induction medium containing 40 µM BrdU.
    19. Count the cells with a hemocytometer. Plate approximately 2.5 × 106 cells per 10 cm dish into precoated dishes by diluting the cells in 6 mL of Complete Induction medium containing 40 µM BrdU without removing the coating solution added in step 2.1.14.
    20. On day 4, aspirate the medium, wash the cells 1x with DPBS, and add fresh Complete Induction medium containing 40 µM BrdU.
    21. On day 6, aspirate the medium, wash the cells 1x with DPBS, and add Neuron medium supplemented with 1 µg/mL of laminin.
    22. At day 9, change 1/3rd of the medium by replacing it with fresh Neuron medium supplemented with 1 µg/mL of laminin.
    23. Maintain i3LMNs for an additional 25 days by performing half medium changes with Neuron medium supplemented with fresh 1 µg/mL of laminin every 3-4 days.
      NOTE: At this timepoint, i3LMNs should present a neuronal morphology with long processes. Neurons also tend to form clumps or clusters of cells. A more detailed description of how to validate the differentiation of i3LMNs can be found elsewhere17.
  2. Synaptosome purification and labeling
    NOTE: Maintain sterile conditions and perform all steps inside a biosafety cabinet.
    1. Wash i3 LMNs twice with DPBS.
    2. Add 2 mL of ice-cold cell lysis reagent for isolation of synaptosomes, incubate on ice for 2 min, and firmly scrape the neurons.
    3. Transfer the lysate to multiple 2 mL microtubes (~1.5 mL lysate per tube) and centrifuge at 1,200 × g for 10 min at 4 °C.
      NOTE: Maintain the tubes on ice throughout this procedure.
    4. Collect the supernatant (discard the pellet) and centrifuge at 15,000 × g for 20 min at 4 °C. Save and resuspend the pellet containing the synaptosomes with a similar volume (as the original lysate) of 5% DMSO in DPBS.
      NOTE: The synaptosomes can be immediately labeled with a fluorophore or stored at -80 °C for future use.
    5. Perform a Bicinchoninic acid (BCA) protein assay for all tubes to assess the total yield of protein in the synaptosome preparation.
      NOTE: Other assays to measure protein concentration can be used. The total protein yield obtained from different preparations has been included in Table 1 as a reference. It is recommended to perform western blot analysis of the synaptosome preparation to confirm the presence of presynaptic and postsynaptic proteins. Here, the presynaptic marker, synaptophysin (SYP), and the postsynaptic marker, postsynaptic density protein 95 (PSD95) were chosen for western blotting analysis as described previously19.
    6. Prepare a solution of 100 mM sodium bicarbonate in water, adjust the pH to 8.5, and sterile-filter.
    7. Solubilize 1 mg of lyophilized powder of the used pH-sensitive dye into 150 µL of DMSO. Make single-use aliquots and store them at -80 °C.
    8. Centrifuge the synaptosomes at 15,000 × g for 5 min at 4 °C.
    9. Dilute up to 1 mg of synaptosomes in 100 µL of 100 mM sodium bicarbonate solution.
    10. To label the synaptosomes, add 1 µL of the reconstituted pH-sensitive dye per 1 mg of synaptosomes and cover the reaction with aluminum foil to avoid light exposure. Shake at room temperature for 2 h using a tube shaker.
    11. Add 1 mL of DPBS to the tube and centrifuge the labeled synaptosomes at 15,000 × g for 5 min at 4 °C.
    12. Remove the supernatant and perform four additional washes as described in step 2.2.11.
    13. After the final wash and spin, remove the supernatant as much as possible without disturbing the pellet and resuspend the labeled synaptosomes with 5% DMSO in DPBS at a volume for the desired concentration (0.7 µg/µL used here). Prepare single-use aliquots and store at -80 °C. Be sure to avoid light exposure to the labeled synaptosomes.
  3. Live-cell phagocytosis assay
    1. Plate 20-30 × 104 PMPs into 96-well plates in 100 µL of iMG complete medium and follow the differentiation process for 10 days as indicated in step 1.2.4.
    2. On the day of the assay, prepare the nuclear staining solution by adding 1 drop of a nuclear stain for live cells into 2 mL of iMG basal medium.
    3. Remove 40 µL of medium per well of the 96-well plate and add 10 µL of the nuclear staining solution using a multichannel pipette. Incubate the plate at 37 °C and 5% CO2 for 2 h.
    4. Thaw the labeled synaptosomes on ice and gently sonicate using a water sonicator for 1 min. Immediately transfer the synaptosomes back to ice. Dilute the labeled synaptosomes in iMG complete medium at a ratio of 1 µL of synaptosomes per 50 µL of medium.
      NOTE: The concentration of synaptosome is assay-dependent and may require optimization. To maintain a relatively low percentage (i.e., 0.1% or less) of DMSO in the medium, it is advised not to add more than 2 µL of synaptosomes per well.
    5. As negative control, pretreat some of the wells with cytochalasin D to inhibit actin polymerization and thus phagocytosis. Prepare a solution of 60 µM cytochalasin D in iMG complete medium. Add 10 µL of this solution to each well for a final concentration of 10 µM and incubate at 37 °C and 5% CO2 for 30 min.
    6. Remove the plate from the incubator and incubate at 10 °C for 10 min. Maintain the plate on ice and add 50 µL of medium containing synaptosomes prepared as described in step 2.3.4.
    7. Centrifuge the plate at 270 × g for 3 min at 10 °C and maintain the plate on ice until imaging acquisition.
  4. Imaging acquisition and analysis
    1. Insert the plate into a live-cell imaging reader and select the wells to be analyzed.
    2. Select a 20x objective lens.
    3. Adjust the focus, light-emitting diode (LED) intensity, integration time, and gain of the brightfield and blue (4',6-diamidino-2-phenylindole [DAPI]) channels. The synaptosome fluorescence should be negligible at the initial time point. To focus on the red (RFP) channel, use the brightfield channel as a reference. The integration time and gain can vary between experiments; use these initial settings for the red channel: LED: 4, integration time: 250, and gain: 5.
    4. Select the number of individual tiles to be acquired in a montage per well (acquire 16 tiles at the center of the well, thereby imaging approximately 5% of the total well area). Set the temperature to 37 °C and the desired time interval for imaging.
      NOTE: Images were acquired every 1 - 2 h for up to 16 h in this study.
    5. Open the analysis software.
      1. Open the experiment that contains the images. Click on the Data Reduction icon.
      2. In the menu, pick Imaging Stitching under Imaging Processing to create a complete image from the 4 x 4 individual tiles in the montage with the parameters described in Table 2.
      3. Once the stitched images have been created, define an intensity threshold using the DAPI and RFP channels for these images. Open an image and click on Analyze; under Analysis, select Cellular Analysis, and under Detection Channel, pick a stitched image either in the DAPI or RFP channels. Go to the Primary Mask and Count tab and establish a threshold value and object size values that properly select the cell nuclei in the DAPI channel or the synaptosome signal in the RFP channel. Repeat the process with different images until parameters that can be applied to the entire experiment are optimized.
        NOTE: Suggested values can be found in Table 2.
      4. To count the number of nuclei, go to the Data Reduction menu, and under Image Analysis, select Cellular Analysis. Go to the Primary Mask and Count tab and under Channel, select the DAPI stitched images and use the parameters described in Table 2.
      5. Go to the Calculated Metrics tab and select Cell Count. To obtain the area of the synaptosome signal, go to the Data Reduction menu and under Analysis, select Cellular Analysis.
      6. Go to the Primary Mask and Count tab and under Channel, select RFP stitched images and use the parameters detailed in Table 2.
      7. Go to the Calculated Metrics tab and select Object Sum Area. In the Data Reduction tab , click on OK and allow the software to analyze all the acquired images.
      8. Export the Object Sum Area and Cell Count values for each time point. Divide the Object Sum Area by the Cell Count to calculate the normalized area per time point. If comparing multiple treatments or genotypes, calculate the phagocytosis index using equation (1):
        Phagocytosis index equation, formula; diagram for cellular activity analysis in research. (1)
      9. Save the results and integrate the data.

Access restricted. Please log in or start a trial to view this content.

Results

To generate iMGs using this protocol, it is important to start with undifferentiated iPSCs that show compact colony morphology with well-defined edges (Figure 2A). Dissociated iPSCs maintained as described in the EB formation section will form spherical aggregates, termed EBs, which will grow in size until day 4 of differentiation (Figure 2B). Once the EBs are collected and plated in the appropriate conditions for PMP generation, they attach to the Matrigel-coat...

Access restricted. Please log in or start a trial to view this content.

Discussion

The differentiation protocol described here provides an efficient method to obtain iPSC-derived microglia-like cells in ~6-8 weeks with high purity and in a sufficient yield to perform immunofluorescence experiments and other assays that require a higher number of cells. This protocol has yielded up to 1 × 106 iMGs in 1 week, which allows for protein and RNA extraction and corresponding downstream analyses (e.g., RNASeq, qRT-PCR, western blot, mass spectrometry). That said, a limitation of this protocol i...

Access restricted. Please log in or start a trial to view this content.

Disclosures

The authors have no conflicts of interest to declare.

Acknowledgements

The authors thank Michael Ward for providing the WTC11 hNIL iPSC line for motor neuron differentiation and the Jackson Laboratories for supplying the KOLF2.1J WT clone B03 iPSC line used for microglia differentiation. We also thank Dorothy Schafer for her support during the implementation of the protocols, Anthony Giampetruzzi and John Landers for their help with the live-cell imaging system as well as Hayden Gadd for his technical contributions during revisions and Jonathan Jung for his collaboration in this study. This work was supported by the Dan and Diane Riccio Fund for Neuroscience from UMASS Chan Medical School and the Angel Fund, Inc.

Access restricted. Please log in or start a trial to view this content.

Materials

List of materials used in this article
NameCompanyCatalog NumberComments
Antibodies for immunofluorescence analysis
anti-IBA1 rabbit antibodyWako Chemical USANC92883641:350 dilution
anti-P2RY12 rabbit antibodySigma-AldrichHPA0145181:50 dilution
anti-TMEM119 rabbit antibodySigma-AldrichHPA0518701:100 dilution
Antibodies for Western blot analysis
anti-β-Tubulin rabbit antibodyAbcamab60461:500 dilution
anti-Synaptophysin (SYP) rabbit antibodyAbclonalA63441:1,000 dilution
anti-PSD95 mouse antibodyMilliporeMAB15961:500 dilution
Borate buffer components
Boric acid (100 mM)SigmaB6768
Sodium bicarbonate (NaHCO3) BioXtraSigma-AldrichS6297-250G
Sodium chloride (75 mM)Sigma S7653
Sodium tetraborate (25 mM)Sigma221732
Cell culture materials
6-well platesGreiner Bio-One657160
40 μm Cell Strainers Falcon352340
100 mm x 20 mm Tissue Culture TreatedCELLTREAT229620
Cell Lifter, Double End, Flat Blade & Narrow Blade, SterileCELLTREAT229305
low adherence round-bottom 96-well plateCorning7007
Primaria 24-well Flat Bottom Surface Modified Multiwell Cell Culture PlateCorning353847,
Primaria 6-well Cell Clear Flat Bottom Surface-Modified Multiwell Culture PlateCorning353846
Primaria 96-well Clear Flat Bottom MicroplateCorning353872
Cell dissociation reagents
Accutase Corning25058CIdissociation reagents used for lower motor neuron differentiation
TrypLE reagentLife Technologies12-605-010dissociation reagents used for microglia differentiation
UltraPure 0.5 M EDTA, pH 8.0Invitrogen15575020
Coating reagents for cell culture
Matrigel GFR Membrane MatrixCorning™354230Referred as to extracellular matrix coating reagent
CellAdhere Laminin-521STEMCELL Technology77004Referred as to laminin 521
Poly-D-LysineSigmaP7405Reconstitute to 0.1 mg/mL in borate buffer
Poly-L-OrnithineSigma P3655Reconstitute to 1 mg/mL in borate buffer
Components of iPSC media
 mTeSR Plus KitSTEMCELL Technology100-0276To prepare iPSC media mixed the components to 1x
Components of EB media
BMP-4Fisher ScientificPHC9534final concentration 50 ng/mL
iPSC mediafinal concentration 1x
ROCK inhibitor Y27632Fisher ScientificBD 562822final concentration 10 µM
SCFPeproTech300-07final concentration 20 ng/mL
VEGFPeproTech100-20Afinal concentration 50 ng/mL
Components of PMP base media
GlutaMAXGibco35050061final concentration 1x
Penicillin-Streptomycin (10,000 U/mL)Gibco15140122final concentration 100 U/mL
X-VIVO 15Lonza12001-988final concentration 1x
Components of PMP complete media
55 mM 2-mercaptoethanolGibco21985023final concentration 55 µM
IL-3PeproTech200-03final concentration 25 ng/mL
M-CSFPeproTech300-25final concentration 100 ng/mL
PMP base mediafinal concentration 1x
Components of iMG base media
Advanced DMEM/F12Gibco12634010final concentration 1x
GlutaMAXGibco35050061final concentration 1x
N2 supplement, 100xGibco17502-048final concentration 1x
Penicillin-Streptomycin (10,000 U/mL)Gibco15140122final concentration 100 U/mL
Components of iMG complete media
55 mM 2-mercaptoethanolGibco21985023final concentration 55 µM
IL-34PeproTech or Biologend200-34 or 577904final concentration 100 ng/mL
iMG base mediafinal concentration 1x
M-CSFPeproTech300-25final concentration 5 ng/mL
TGF-βPeproTech100-21final concentration 50 ng/mL
Components of Induction base media
DMEM/F12 with HEPESGibco11330032final concentration 1x
GlutaMAXGibco35050061final concentration 1x
N2 supplement, 100xGibco17502-048final concentration 1x
Non-essential amino acids (NEAA), 100xGibco11140050final concentration 1x
Components of Complete induction media
Compound ECalbiochem565790final concentration 0.2 μM and reconstitute stock reagent to 2 mM in 1:1 ethanol and DMSO
DoxycyclineSigmaD9891final concentration 2 μg/mL and reconstitute stock reagent to 2 mg/mL in DPBS
Induction base mediafinal concentration 1x
ROCK inhibitor Y27632Fisher ScientificBD 562822final concentration 10 μM
Components of Neuron media
B-27 Plus Neuronal Culture SystemGibcoA3653401final concentration 1x for media and suplemment
GlutaMAXGibco35050061final concentration 1x
N2 supplement, 100xGibco17502-048final concentration 1x
Non-essential amino acids (NEAA), 100xGibco11140050final concentration 1x
iPSC lines used in this study
KOLF2.1J: WT clone B03The Jackson Laboratories
WTC11 hNILNational Institute of Health
Synaptosome isolation reagents
BCA Protein Assay KitThermo Scientific Pierce23227
dimethyl sulfoxide (DMSO)SigmaD2650
Syn-PER Synaptic Protein Extraction ReagentThermo Scientific87793Referred as to cell lysis reagent for isolation of synaptosomes
Phagocytosis assay dyes
NucBlue Live Ready reagentInvitrogen R37605
pHrodo Red, succinimidyl esterThermoFisher Scientific P36600Referred as to pH-sensitive dye
Other cell-culture reagents
Trypan Blue, 0.4% SolutionAMRESCO INCK940-100ML
Bovine serum albumin (BSA)Sigma22144-77-0
BrdUSigmaB9285Reconstitute to 40 mM in sterile water
Cytochalasin DSigmafinal concentration 10 µM
DPBS with Calcium and magnesiumCorning21-030-CV
DPBS without calcium and magnesiumCorning21-031-CVReferred as to DPBS
KnockOut  DMEM/F-12Gibco12660012Referred as to DMEM-F12 optimized for growth of human embryonic and induced pluripotent stem cells
Laminin Mouse Protein, NaturalGibco23017015Referred as to laminin
Software and Equipment
CentrifugeEppendorfModel 5810R
Cytation 5 live cell imaging readerBiotek
Gen5 Microplate Reader and Imager SoftwareBiotekversion 3.03
Multi-Therm Heat-ShakeBenchmarkrefer as tube shaker
Water sonicatorElmaMode Transsonic 310

References

  1. Heider, J., Vogel, S., Volkmer, H., Breitmeyer, R. Human iPSC-derived glia as a tool for neuropsychiatric research and drug development. International Journal of Molecular Sciences. 22 (19), 10254(2021).
  2. Muzio, L., Viotti, A., Martino, G. Microglia in neuroinflammation and neurodegeneration: from understanding to therapy. Frontiers in Neuroscience. 15, 742065(2021).
  3. Galatro, T. F., et al. Transcriptomic analysis of purified human cortical microglia reveals age-associated changes. Nature Neuroscience. 20 (8), 1162-1171 (2017).
  4. Gosselin, D., et al. An environment-dependent transcriptional network specifies human microglia identity. Science. 356 (6344), (2017).
  5. Haimon, Z., et al. Re-evaluating microglia expression profiles using RiboTag and cell isolation strategies. Nature Immunology. 19 (6), 636-644 (2018).
  6. Abud, E. M., et al. iPSC-derived human microglia-like cells to study neurological diseases. Neuron. 94 (2), 278-293 (2017).
  7. Brownjohn, P. W., et al. Functional studies of missense TREM2 mutations in human stem cell-derived microglia. Stem Cell Reports. 10 (4), 1294-1307 (2018).
  8. Haenseler, W., et al. A highly efficient human pluripotent stem cell microglia model displays a neuronal-co-culture-specific expression profile and inflammatory response. Stem Cell Reports. 8 (6), 1727-1742 (2017).
  9. McQuade, A., et al. Development and validation of a simplified method to generate human microglia from pluripotent stem cells. Molecular Neurodegeneration. 13 (1), 1-13 (2018).
  10. Muffat, J., et al. Efficient derivation of microglia-like cells from human pluripotent stem cells. Nature Medicine. 22 (11), 1358-1367 (2016).
  11. Haenseler, W., Rajendran, L. Concise review: modeling neurodegenerative diseases with human pluripotent stem cell-derived microglia. Stem Cells. 37 (6), 724-730 (2019).
  12. Wilgenburg, B. v, Browne, C., Vowles, J., Cowley, S. A. Efficient, long term production of monocyte-derived macrophages from human pluripotent stem cells under partly-defined and fully-defined conditions. PloS One. 8 (8), 71098(2013).
  13. Hoeffel, G., Ginhoux, F. Ontogeny of tissue-resident macrophages. Frontiers in Immunology. 6, 486(2015).
  14. Janda, E., Boi, L., Carta, A. R. Microglial phagocytosis and its regulation: a therapeutic target in Parkinson's disease. Frontiers in Molecular Neuroscience. 11, 144(2018).
  15. Schafer, D. P., Stevens, B. Microglia function in central nervous system development and plasticity. Cold Spring Harbor Perspectives in Biology. 7 (10), 020545(2015).
  16. Nau, R., Ribes, S., Djukic, M., Eiffert, H. Strategies to increase the activity of microglia as efficient protectors of the brain against infections. Frontiers in Cellular Neuroscience. 8, 138(2014).
  17. Fernandopulle, M. S., et al. Transcription factor-mediated differentiation of human iPSCs into neurons. Current Protocols in Cell Biology. 79 (1), 51(2018).
  18. Gutbier, S., et al. Large-scale production of human IPSC-derived macrophages for drug screening. International Journal of Molecular Sciences. 21 (13), 4808(2020).
  19. Sellgren, C., et al. Patient-specific models of microglia-mediated engulfment of synapses and neural progenitors. Molecular Psychiatry. 22 (2), 170-177 (2017).
  20. Schmidt, E. J., et al. ALS-linked PFN1 variants exhibit loss and gain of functions in the context of formin-induced actin polymerization. Proceedings of the National Academy of Sciences of the United States of America. 118 (23), (2021).
  21. Miksa, M., Komura, H., Wu, R., Shah, K. G., Wang, P. A novel method to determine the engulfment of apoptotic cells by macrophages using pHrodo succinimidyl ester. Journal of Immunological Methods. 342 (1-2), 71-77 (2009).

Access restricted. Please log in or start a trial to view this content.

Reprints and Permissions

Tags

Microglia DifferentiationSynaptosome AssayImmunofluorescent StainingWestern BlotNeurodegenerative Diseases
Human Microglia-like Cells: Differentiation from Induced Pluripotent Stem Cells and In Vitro Live-cell Phagocytosis Assay using Human Synaptosomes
Contact Us
Recommend to Library

Privacy

Terms of Use

Policies

Copyright © 2026 MyJoVE Corporation. All rights reserved.